Metabolism and mode of inhibition of varicella-zoster virus by L-beta-5-bromovinyl-(2-hydroxymethyl)-(1,3-dioxolanyl)uracil is dependent on viral thymidine kinase.

A nonnaturally occurring L-configuration nucleoside analog, L-beta-5-bromovinyl-(2-hydroxymethyl)-1,3-(dioxolanyl)uracil (L-BVOddU) selectively inhibited varicella-zoster virus growth in human embryonic lung (HEL) 299 cell culture with an EC(50) of 0.055 microM, whereas no inhibition of CEM and HEL 299 cell growth or mitochondrial DNA synthesis was observed at concentrations up to 200 microM. L-BVOddU was phosphorylated by viral thymidine kinase but not by human cytosolic thymidine kinase, and the antiviral activity of this compound is dependent on the viral thymidine kinase. Unlike other D-configuration bromovinyl deoxyuridine analogs, such as E-5-(2-bromovinyl)-2'-deoxyuridine and 1-beta-arabinofuranosyl-E-5-(2-bromovinyl)uracil, this compound was metabolized only to its monophosphate metabolite. The di- or triphosphate metabolites were not detected. This suggested that the inhibitory mechanism may be unique and different from other anti-herpesvirus nucleoside analogs.

[1]  Y. Cheng,et al.  Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses. , 2000, Journal of medicinal chemistry.

[2]  Y. Cheng,et al.  Structure-activity relationships of L-dioxolane uracil nucleosides as anti-Epstein Barr virus agents. , 1999, Journal of medicinal chemistry.

[3]  R. Diasio,et al.  Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. , 1998, British journal of clinical pharmacology.

[4]  M. Kukhanova,et al.  Metabolism of 2′,3′-Dideoxy-2′,3′-Didehydro-β-l(−)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Human Immunodeficiency Virus β-d(+) Nucleoside Analogs In Vitro , 1998, Antimicrobial Agents and Chemotherapy.

[5]  C. Crumpacker,et al.  Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial , 1998, Antimicrobial Agents and Chemotherapy.

[6]  C. K. Chu,et al.  Synthesis and Anti-Hepatitis B Virus Activity of 9-(2-Deoxy-2-fluoro-. beta.-L-arabinofuranosyl)purine Nucleosides. , 1997 .

[7]  M. Newton,et al.  Synthesis and Anti-Hepatitis B Virus Activity of 9-(2-Deoxy-2-fluoro-β-l-arabinofuranosyl)purine Nucleosides , 1997 .

[8]  S. Akimoto,et al.  Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. , 1997, Pharmacogenetics.

[9]  Y. L. Zhu,et al.  Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. , 1996, Journal of medicinal chemistry.

[10]  E. Gullen,et al.  Design and Synthesis of 2‘,3‘-Dideoxy- 2‘,3‘-didehydro-β-l-cytidine (β-l-d4C) and 2‘,3‘-Dideoxy-2‘,3‘-didehydro-β-l-5- fluorocytidine (β-l-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro , 1996 .

[11]  M. Kukhanova,et al.  Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. , 1996, Biochemical pharmacology.

[12]  Y. Cheng,et al.  Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. , 1995, Cancer research.

[13]  Y. Cheng,et al.  Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus , 1995, Antimicrobial agents and chemotherapy.

[14]  T. Mansour,et al.  Inhibitory activities of herpes simplex viruses type 1 and 2 and human cytomegalovirus by stereoisomers of 2′-deoxy-3′-oxa-5(E)-(2-bromovinyl)uridines and their 4′-thio analogues. , 1994 .

[15]  E. De Clercq,et al.  Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. , 1993, The Journal of biological chemistry.

[16]  R. Schinazi,et al.  Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. , 1992, The Journal of biological chemistry.

[17]  Y. Cheng,et al.  Suppression of ocular herpes recurrences by a thymidine kinase inhibitor in squirrel monkeys. , 1991, Antiviral research.

[18]  T. Yokota,et al.  Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. , 1989, Molecular pharmacology.

[19]  C. H. Chen,et al.  Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. , 1989, The Journal of biological chemistry.

[20]  E. De Clercq,et al.  Incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of varicella-zoster virus (TK+ and TK- strains)-infected cells. , 1987, Molecular pharmacology.

[21]  E. De Clercq,et al.  Comparative metabolism of E-5-(2-bromovinyl)-2'-deoxyuridine and 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in herpes simplex virus-infected cells. , 1987, Molecular pharmacology.

[22]  Y. Cheng,et al.  Demonstration of viral thymidine kinase inhibitor and its effect on deoxynucleotide metabolism in cells infected with herpes simplex virus , 1987, Antimicrobial Agents and Chemotherapy.

[23]  E. De Clercq,et al.  Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate. , 1984, Molecular pharmacology.

[24]  H. Machida,et al.  In vitro and in vivo antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds. , 1984, Antiviral research.

[25]  E. De Clercq,et al.  Differential binding affinities of sugar-modified derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine for herpes simplex virus-induced and human cellular deoxythymidine kinases. , 1984, Biochemical pharmacology.

[26]  E. De Clercq,et al.  Phosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted-2'-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets. , 1983, Biochemical pharmacology.

[27]  Y. Cheng,et al.  Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases , 1981, Antimicrobial Agents and Chemotherapy.

[28]  Y. Cheng,et al.  Nucleoside analogues with clinical potential in antivirus chemotherapy. The effect of several thymidine and 2'-deoxycytidine analogue 5'-triphosphates on purified human (alpha, beta) and herpes simplex virus (types 1, 2) DNA polymerases. , 1981, Molecular pharmacology.

[29]  R. T. Walker,et al.  Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins. , 1981, Molecular pharmacology.

[30]  R. T. Walker,et al.  Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. , 1980, The Journal of infectious diseases.

[31]  T. Hackstadt,et al.  Induction of thymidine kinase and DNase in varicella-zoster virus-infected cells and kinetic properties of the virus-induced thymidine kinase , 1979, Journal of virology.

[32]  R. T. Walker,et al.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. , 1979, Proceedings of the National Academy of Sciences of the United States of America.